Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
10’705 GBX | -0.34% | +2.64% | +0.98% |
27.03. | AstraZeneca CEO sieht keine Auswirkungen des Biosecure Act | MT |
27.03. | AstraZenecas RSV-Medikament und Brustkrebs-Kombinationstherapie erhalten Zulassung in Japan | MT |
ETFs investiert in AstraZeneca PLC
Name | Gewichtung | Volumen | % 1. Jan. | Investm. Rating |
---|---|---|---|---|
9,20% | 11 M€ | +0.83% | - | |
5,39% | 196 M€ | +12.07% | ||
5,17% | 18 M€ | +7.01% | - | |
4,89% | 770 M€ | +6.65% | ||
4,11% | 88 M€ | +10.37% | - | |
3,47% | 222 M€ | +8.22% | ||
2,74% | 4 M€ | -.--% | - | |
2,57% | 6 M€ | -.--% | ||
2,53% | 4 M€ | +8.68% | - | |
2,53% | 1 407 M€ | +4.66% | ||
1,54% | 29 M€ | +8.37% | - | |
1,51% | 2 M€ | +9.19% | - | |
1,51% | 2 M€ | -.--% | - | |
1,26% | 12 M€ | +15.09% | - | |
1,19% | 49 M€ | +6.84% | ||
1,16% | 10 M€ | -3.35% | - | |
0,97% | 7 M€ | +4.41% | - | |
0,89% | 30 M€ | +5.34% | - | |
0,86% | 276 M€ | +11.40% | - | |
0,70% | 268 M€ | -.--% | - | |
0,69% | 193 M€ | +9.76% | - | |
0,69% | 460 M€ | +12.09% | ||
0,57% | 205 M€ | -.--% | ||
0,54% | 284 M€ | -.--% | ||
0,51% | 786 M€ | -.--% | ||
0,51% | 23 M€ | -.--% | - | |
0,50% | 206 M€ | -.--% | ||
0,48% | 673 M€ | +8.91% | ||
0,43% | 274 M€ | +15.39% |
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+0.98% | 210 Mrd. | |
+33.50% | 701 Mrd. | |
+26.24% | 571 Mrd. | |
+0.78% | 381 Mrd. | |
+20.85% | 334 Mrd. | |
+16.38% | 319 Mrd. | |
+2.75% | 210 Mrd. | |
-6.77% | 201 Mrd. | |
-3.51% | 157 Mrd. | |
-0.60% | 153 Mrd. |
- Börse
- Aktien
- Aktie AstraZeneca PLC - London S.E.
- ETFs AstraZeneca PLC